Want to see GB:APTA full AI Analyst Report?
Top Page
Aptamer Group Plc
(LSE:APTA)
Select Model
Select Model
Rating:40Underperform
Price Target:
0.45 p
▼(-43.63% Downside)
Action:Downgraded
Date:03/25/26
The score is primarily held down by very weak financial performance (sharp revenue collapse, continued losses, and negative cash flows). Technical indicators also remain bearish with the stock below major moving averages and negative MACD; oversold momentum readings provide only limited support. Valuation is constrained by a negative P/E and no dividend data.
Positive Factors
Specialized aptamer platform
Aptamer Group's core business is a specialized platform for aptamer discovery and development used in diagnostics, research and potential therapeutics. This niche technical capability supports durable service revenues, partner integration and IP-driven differentiation over medium term horizons.
Negative Factors
Severe revenue decline
A near-total collapse in revenue undermines scale economics, partner confidence and the firm's ability to fund R&D internally. Without a clear, sustained revenue recovery, the business faces structural challenges to sustaining operations and executing long-term growth plans.
Read all positive and negative factors
Positive Factors
Negative Factors
Specialized aptamer platform
Aptamer Group's core business is a specialized platform for aptamer discovery and development used in diagnostics, research and potential therapeutics. This niche technical capability supports durable service revenues, partner integration and IP-driven differentiation over medium term horizons.
Read all positive factors
Aptamer Group Plc (APTA) vs. iShares MSCI United Kingdom ETF (EWC)
Market Cap
£16.41M
Dividend YieldN/A
Average Volume (3M)15.29M
Price to Earnings (P/E)―
Beta (1Y)0.23
Revenue Growth13.42%
EPS Growth65.63%
CountryUK
Employees28
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding3,455,144,000
10 Day Avg. Volume14,821,052
30 Day Avg. Volume15,285,032
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)5.32
Price to Sales (P/S)6.11
P/FCF Ratio-3.66
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Aptamer Group Plc Business Overview & Revenue Model
Company Description
Aptamer Group plc, an international company headquartered in York, United Kingdom, specializes in providing advanced binders for applications spanning research, diagnostics, and therapeutics. Their innovative binder technology is engineered to res...
How the Company Makes Money
null...
Aptamer Group Plc Financial Statement Overview
Summary
Income Statement
25
Negative
Balance Sheet
40
Negative
Cash Flow
30
Negative
| Breakdown | TTM | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.38M | 1.20M | 860.00K | 1.75M | 4.04M | 1.28M |
| Gross Profit | 438.00K | 350.00K | 250.00K | 359.00K | 2.69M | 538.40K |
| EBITDA | -2.39M | -2.28M | -2.81M | -7.36M | -2.19M | -2.24M |
| Net Income | -2.46M | -2.42M | -2.96M | -7.84M | -2.09M | -1.85M |
Balance Sheet | ||||||
| Total Assets | 3.73M | 2.83M | 2.77M | 2.75M | 11.52M | 2.06M |
| Cash, Cash Equivalents and Short-Term Investments | 1.53M | 1.06M | 870.00K | 234.00K | 6.69M | 369.00K |
| Total Debt | 333.00K | 491.00K | 817.00K | 1.08M | 1.31M | 78.00K |
| Total Liabilities | 1.48M | 1.45M | 1.88M | 2.45M | 3.47M | 1.96M |
| Stockholders Equity | 2.25M | 1.38M | 887.00K | 304.00K | 8.05M | 105.00K |
Cash Flow | ||||||
| Free Cash Flow | -1.93M | -2.01M | -2.41M | -6.09M | -2.79M | -1.26M |
| Operating Cash Flow | -1.91M | -2.00M | -2.28M | -4.06M | -2.38M | -1.10M |
| Investing Cash Flow | -102.00K | -92.00K | -122.00K | -2.03M | -418.00K | -339.20K |
| Financing Cash Flow | 1.57M | 2.28M | 3.04M | -365.00K | 9.12M | 1.50M |
Aptamer Group Plc Technical Analysis
Negative
0.80
Price Trends
0.53
Negative
0.63
Negative
0.76
Negative
Market Momentum
-0.02
Positive
33.37
Neutral
45.35
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:APTA, the sentiment is Negative. The current price of 0.8 is above the 20-day moving average (MA) of 0.50, above the 50-day MA of 0.53, and above the 200-day MA of 0.76, indicating a bearish trend. The MACD of -0.02 indicates Positive momentum. The RSI at 33.37 is Neutral, neither overbought nor oversold. The STOCH value of 45.35 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GB:APTA.
Aptamer Group Plc Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
75 Outperform | £83.60M | 11.06 | 65.83% | 8.33% | -8.21% | -5.27% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | £320.86M | -7.41 | -2929.47% | ― | ― | ― | |
46 Neutral | £23.98M | 36.08 | -197.54% | ― | ― | ― | |
44 Neutral | £13.77M | -7.47 | -210.32% | ― | -11.43% | 23.40% | |
40 Underperform | £16.41M | -7.92 | -213.66% | ― | 13.42% | 65.63% | |
39 Underperform | £4.29M | -0.26 | -316.67% | ― | 33.37% | 86.41% |
* Healthcare Sector Average
GB:APTA
Aptamer Group Plc
0.48
0.07
18.75%
GB:AVCT
Avacta Group plc
69.00
37.00
115.63%
GB:BVXP
Bioventix
1,570.00
-957.88
-37.89%
GB:OBD
Oxford BioDynamics
0.11
-0.48
-81.90%
GB:FAB
Fusion Antibodies Plc
10.75
4.00
59.26%
GB:AREC
Arecor Therapeutics PLC
63.50
14.50
29.59%
Aptamer Group Plc Corporate Events
Business Operations and StrategyFinancial DisclosuresPrivate Placements and Financing
Aptamer Group lifts revenue and pipeline as high-margin licensing takes hold
Positive
Jul 13, 2026
Aptamer Group reported expected revenue of about £1.5 million for FY2026, a 25% year-on-year increase driven by fee-for-service work and its first licensing income from Twist Bioscience and Alphazyme. The company’s sales pipeline expand...
Business Operations and StrategyProduct-Related Announcements
Aptamer Group moves to plug Ebola testing gap with Bundibugyo diagnostic push
Positive
Jul 8, 2026
Aptamer Group has launched a programme to develop Optimer binders for a rapid diagnostic test targeting the rare Bundibugyo strain of Ebola, amid the largest recorded outbreak in the Democratic Republic of Congo and Uganda. The initiative responds...
Business Operations and Strategy
Aptamer Group advances AI-driven discovery, automation and therapeutic pipeline after fundraise
Positive
Jun 25, 2026
Aptamer Group has reported strong progress across its AI, automation, and therapeutic development initiatives following its April 2026 fundraise, underscoring growing operational momentum. The company has built and trained an AI model on a large i...
Business Operations and StrategyProduct-Related Announcements
Aptamer partners with Imperial College on Gates-backed folic acid test
Positive
Jun 8, 2026
Aptamer Group has launched a funded research programme with Imperial College London to adapt its folic acid Optimer binders for use in rapid lateral flow tests that monitor folate levels in fortified foods, particularly in lower-income countries. ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.